PharmaPatents Timely Insight on Emerging Legal Developments

Tag Archives: Declaratory Judgment

Federal Circuit Upholds Declaratory Judgment Jurisdiction Over Subsequent ANDA Litigation

Posted by Courtenay Brinckerhoff on Posted in Federal Circuit Decisions; Myriad

In Dey Pharma, LP v. Sunovion Pharmaceuticals, Inc., the Federal Circuit affirmed the district court’s determination that it could exercise jurisdiction over a declaratory judgment action brought by a subsequent ANDA filer. This case follows earlier decisions in Teva Pharmaceuticals USA, Inc. v. Eisai Co., Ltd., Caraco Pharmaceutical Laboratories, Ltd. v. Forest Laboratories, Inc. and Janssen Pharmaceutica, N.V. v. Apotex, Inc., which I discussed in this article, and addresses the circumstances under which a subsequent ANDA filer can bring a declaratory judgment action to challenge Orange Book listed patents when the first ANDA filer has not yet entered the market.Continue reading this entry

Federal Circuit Looks At Requirements For Declaratory Judgment Jurisdiction

Posted by Courtenay Brinckerhoff on Posted in Federal Circuit Decisions; Myriad

In 3M Co. v. Avery Dennison Corp., the Federal Circuit vacated and remanded the district court’s decision to dismiss 3M’s declaratory judgment action for lack of jurisdiction. Although the Federal Circuit did not render a decision in this case, its analysis sheds light on a scenario that might support declaratory judgment jurisdiction.Continue reading this entry

The Federal Circuit Solidifies The Future For Subsequent ANDA Litigation

Posted by Courtenay Brinckerhoff on Posted in Federal Circuit Decisions

In Teva Pharmaceuticals USA, Inc. v. Eisai Co., Ltd., the Federal Circuit addressed complicated subject matter jurisdiction issues in the context of a declaratory judgment (DJ) action that was brought in accordance with the Hatch-Waxman Act by a subsequent ANDA filer. The court determined that the DJ action should proceed, even though the patent owner could not have brought an infringement action to enforce the challenged patents. The court’s decision may encourage DJ actions by other subsequent ANDA filers, with the potential to hasten the market entry of more generic drug products.

Continue reading this entry